Wen-Tsan Chang Selected Research

Wen-Tsan Chang Research Topics

Disease

33	Neoplasms (Cancer) 05/2022 - 04/2008
19	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 10/2004
8	Infections 10/2021 - 05/2002
6	Neoplasm Metastasis (Metastasis) 08/2021 - 03/2004
6	Lung Neoplasms (Lung Cancer) 06/2017 - 12/2010
4	Type 2 Diabetes Mellitus (MODY) 01/2019 - 01/2012
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 01/2014
3	Carcinogenesis 01/2021 - 01/2012
3	Inflammation (Inflammations) 08/2020 - 06/2011
3	Liver Cirrhosis (Hepatic Cirrhosis) 03/2013 - 09/2008
2	Wound Infection (Wound Infections) 11/2022 - 08/2004
2	Sepsis (Septicemia) 05/2022 - 10/2021
2	Fistula 05/2022 - 01/2012
2	Disease Progression 01/2021 - 07/2018
2	Necrosis 08/2020 - 06/2011
2	Breast Neoplasms (Breast Cancer) 09/2019 - 01/2017
2	Lewis Lung Carcinoma 01/2018 - 01/2017
2	Diabetic Nephropathies (Diabetic Nephropathy) 10/2016 - 01/2012
2	Chronic Hepatitis C 12/2015 - 11/2008
2	Insulin Resistance 08/2013 - 01/2012
2	Adenocarcinoma of Lung 01/2013 - 12/2010
2	Obesity 06/2011 - 02/2006
2	Fibrosis (Cirrhosis) 09/2008 - 04/2005
2	Chronic Hepatitis B 04/2005 - 10/2004
1	Hyperamylasemia 11/2022
1	Lacerations 05/2022
1	Liver Abscess 05/2022
1	Critical Illness (Critically Ill) 01/2022
1	Pancreatic Neoplasms (Pancreatic Cancer) 08/2021
1	Glioma (Gliomas) 04/2021
1	Astrocytoma (Pilocytic Astrocytoma) 04/2021
1	Cholangiocarcinoma 01/2021
1	Prostatic Neoplasms (Prostate Cancer) 01/2021
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021
1	Chromosome Breakage 12/2020
1	Circulating Neoplastic Cells 11/2020

Drug/Important Bio-Agent (IBA)

9	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2008
5	CeramidesIBA 05/2022 - 04/2008
5	Fibronectins (Fibronectin)IBA 04/2021 - 01/2017
4	EnzymesIBA 04/2018 - 01/2012
4	Small Interfering RNA (siRNA)IBA 01/2018 - 09/2008
3	Sorafenib (BAY 43-9006)FDA Link 01/2022 - 07/2018
3	N-acetylsphingosineIBA 03/2021 - 01/2014
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2019
3	Messenger RNA (mRNA)IBA 09/2019 - 11/2004
3	Epirubicin (Ellence)FDA LinkGeneric 01/2018 - 01/2014
3	Interleukin-6 (Interleukin 6)IBA 10/2016 - 12/2010
3	eugenosedin-AIBA 03/2014 - 06/2011
3	Surface Antigens (Surface Antigen)IBA 06/2010 - 10/2004
3	Anti-Bacterial Agents (Antibiotics)IBA 06/2006 - 05/2002
2	Biological ProductsIBA 01/2021 - 01/2012
2	Reactive Oxygen Species (Oxygen Radicals)IBA 08/2020 - 01/2017
2	micaIBA 10/2018 - 12/2015
2	pterostilbeneIBA 01/2018 - 01/2017
2	AnthracyclinesIBA 01/2018 - 05/2014
2	CamptothecinIBA 06/2017 - 01/2016
2	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 06/2017 - 01/2016
2	Arecoline (Arecolin)IBA 01/2017 - 01/2012
2	LipidsIBA 01/2017 - 04/2008
2	AlbuminsIBA 10/2016 - 09/2008
2	CreatinineIBA 10/2016 - 11/2012
2	Indocyanine Green (Cardio-Green)FDA LinkGeneric 08/2015 - 11/2012
2	Progesterone FDA LinkGeneric 05/2014 - 01/2014
2	Pharmaceutical PreparationsIBA 05/2014 - 12/2010
2	LeptinIBA 08/2013 - 02/2006
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2013 - 01/2013
2	Serum AlbuminIBA 11/2012 - 08/2004
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2012 - 12/2010
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 06/2011 - 11/2003
2	LipopolysaccharidesIBA 01/2006 - 11/2005
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 10/2005 - 10/2004
2	Membrane Proteins (Integral Membrane Proteins)IBA 04/2005 - 11/2004
1	SphingolipidsIBA 05/2022
1	perfluoro- 2,2,2',2'- tetramethyl- 4,4'- bis(1,3- dioxolane)IBA 05/2022
1	regorafenibIBA 01/2022
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2022
1	VimentinIBA 04/2021
1	Transforming Growth Factor beta (TGF-beta)IBA 04/2021
1	Glycoproteins (Glycoprotein)IBA 04/2021
1	Indicators and Reagents (Reagents)IBA 03/2021
1	ForminsIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Terpenes (Terpenoids)IBA 01/2021
1	Untranslated RNA (Noncoding RNA)IBA 01/2021
1	Long Noncoding RNAIBA 01/2021
1	heteroneminIBA 01/2021
1	CDC2 Protein Kinase (Protein p34cdc2)IBA 01/2021
1	A-Form DNA (A-DNA)IBA 12/2020
1	Methyl MethanesulfonateIBA 12/2020
1	CaspasesIBA 08/2020
1	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 01/2020

Therapy/Procedure

6	Therapeutics 05/2022 - 12/2015
5	Drug Therapy (Chemotherapy) 08/2021 - 04/2008
3	Liver Transplantation 10/2021 - 01/2012
2	Splenectomy 01/2013 - 11/2008
1	Conservative Treatment 11/2022
1	Transplantation 05/2022
1	Salvage Therapy 01/2022
1	Oral Hygiene (Dental Hygiene) 10/2021
1	Radiotherapy 08/2021